🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Danaher Corporation (DHR)
NYSE: DHR · Real-Time Price · USD
228.58
+2.81 (1.24%)
Nov 18, 2026, 4:00 PM EST - Market closed
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Priorities center on commercial execution, focused R&D, AI and strategic M&A to drive higher growth and share gains. Next year’s 4%-5% core growth ex-respiratory is the starting point; reshoring is expected to contribute more materially from 2028.

Julie Sawyer Montgomery
President and CEO, Danaher

for doing that. I didn't end up doing it.

Moderator

The nice thing is it's very efficient. You can do a master's in one year.

Julie Sawyer Montgomery
President and CEO, Danaher

Yeah.

Moderator

You can do like a PhD. I didn't do a PhD, but you can do it in three years, right?

Julie Sawyer Montgomery
President and CEO, Danaher

Wow.

Moderator

Like, it's pretty quick. Yeah. A lot of Americans do it. It's fun to live abroad.

Julie Sawyer Montgomery
President and CEO, Danaher

I did my undergrad at Columbia, and they had a program where you could spend a year at Oxford or Cambridge.

Moderator

Right. Yeah.

Julie Sawyer Montgomery
President and CEO, Danaher

I considered doing it. I was offered an opportunity to do it, but at the end decided not to. I was having too much fun in New York City.

Moderator

Right. New York.

Julie Sawyer Montgomery
President and CEO, Danaher

And that was great, but I really—

Moderator

Yeah

Julie Sawyer Montgomery
President and CEO, Danaher

—enjoying myself here, so.

Moderator

Did you stay in New York after Columbia?

Julie Sawyer Montgomery
President and CEO, Danaher

I ended up going to grad school at the Eastman School of Music.

Moderator

Oh, okay.

Julie Sawyer Montgomery
President and CEO, Danaher

That's in Rochester, New York.

Moderator

Yeah. Yeah. Okay.

Julie Sawyer Montgomery
President and CEO, Danaher

That was like going from the center of the universe—

Moderator

Right

Julie Sawyer Montgomery
President and CEO, Danaher

—to somewhere I never wanted to be again.

Moderator

That was a year, couple years?

Julie Sawyer Montgomery
President and CEO, Danaher

Couple years.

Moderator

Yeah. Okay.

Julie Sawyer Montgomery
President and CEO, Danaher

I was in Boston.

Moderator

Yeah.

Julie Sawyer Montgomery
President and CEO, Danaher

Spending a lot of time in New York.

Moderator

Yeah.

Julie Sawyer Montgomery
President and CEO, Danaher

Because I was a strategy consultant.

Moderator

Yeah.

Julie Sawyer Montgomery
President and CEO, Danaher

My clients were in New York.

Moderator

Okay. Great. We are going to kick it off. Welcome everybody. I am Tycho Peterson from the Life Science team. It is my pleasure to have Danaher with us this morning. Welcome, Julie.

Julie Sawyer Montgomery
President and CEO, Danaher

Thank you.

Moderator

Maybe we could kick it off with just quick state of the union. You have been in the role just over three weeks. Thinking about some of your key priorities here, innovation, commercial excellence, things you have talked a little bit about. Maybe we could just dive a little bit deeper in there and talk about those two in particular, starting with innovation and what your priorities are and what it takes to really dig in there.

Julie Sawyer Montgomery
President and CEO, Danaher

Yeah. Well, thank you, Tycho, and it's great to be here with you today. The opportunity for Danaher is to be the defining leader in life sciences and diagnostics, and that means higher, sustainable, profitable core growth and unambiguous share gain in our markets. The path to that is on these priorities, commercial excellence, innovation, talent, and capital allocation. If I double-click on commercial, really there's two main things here. One is a focus on DBS commercial excellence. This does not mean rewriting the Danaher Business System, but focusing on those critical but profound priorities like funnel management, good account plans. The second part of this is showing up commercially as a more connected Danaher. Many of our customers buy from three, six, nine, 12 operating companies, but we have not gone to market that way.

This is adding in a key account layer that makes it easier for our customers to access the full power of the Danaher value proposition. In diagnostics, we have started to do this in a very short period of time, created several hundreds of millions of dollars of incremental opportunity. You also asked about innovation, and there it's really about strategy-led innovation, focusing our R&D U.S. dollars on those organic R&D initiatives that are going to drive the most growth for Danaher. We're excited about the journey ahead, and I'm confident that these priorities can result in higher core growth and outperformance in our markets.

Moderator

And maybe just to hone in on the innovation point, I mean, obviously you've always had a lot of innovation through the operating companies.

Julie Sawyer Montgomery
President and CEO, Danaher

Yeah.

Moderator

As we think about it going forward, is there a cultural shift that needs to happen? I mean, is it more centralized decision-making? Just talk about practically how you're implementing that and when we could maybe see it translate to revenues too.

Julie Sawyer Montgomery
President and CEO, Danaher

Sure. The return on investment of innovation is a very important point, one that I am very passionate about, and I have led our innovation engine at Danaher for the last year or so. The opportunity here is really around ensuring that we have an enterprise view to what are those most important investment opportunities. That probably sounds like common sense, but it is newer muscle to Danaher, and I think now is more important that we are a life sciences and diagnostics company. It is important to know where that scientific puck is going and make the right strategic bets. We have started in this journey. We have hired on additional science and technology talent to help us better understand the most important places to index our innovation dollars. It is not about spending more on innovation. We spend about $1.7 billion a year on innovation.

We think that is the right amount. Just to give you an example, in diagnostics, where we started down this path and focused on the most important innovation priorities, we have seen an increase of 80% in our forecasted growth from innovation. Some of this is the ambition and where you are focusing those dollars.

Moderator

I am glad you commented on the absolute amount of spending because it is also not to spend less, right? I mean, you want to kind of—

Julie Sawyer Montgomery
President and CEO, Danaher

No, I do not think we want to spend less. There are a lot of important opportunities in our markets.

Moderator

—Maybe just reflecting back on what you did in diagnostics and some of the strategic priorities, what worked, what didn't. Talk a little bit about lessons learned.

Julie Sawyer Montgomery
President and CEO, Danaher

Diagnostics is Danaher's largest platform, and we have seen some strong underlying growth performance. When I joined Danaher in 2017, our diagnostics business was $6 billion. Today, it is $11 billion with 3x the operating profit. Our core growth, ex-respiratory in China, has more than doubled in the last handful of years. We're proud of what we've done in diagnostics, and it's really that playbook that I'm now talking about for Danaher, the focus on commercial execution, innovation, talent, and capital allocation. Maybe just to give you a concrete example, Leica Biosystems. When I first started working with Leica Biosystems, it was a mid-single-digit grower. Today, it's high single digits. It started with that focus on commercial execution, getting really good at funnel management and account planning.

We also did a lot of analysis of how we were performing compared to the market, and that gives you insights into where you have a commercial execution opportunity or maybe where you have an R&D organic investment opportunity. In the case of Leica Biosystems, we realized that we were underperforming in advanced staining, and that was a commercial execution opportunity. We've seen a lot of progress there. We also started selling through a diagnostic solutions group, and that allowed us to use our strength in other operating companies to help support the pull-in of new competitive wins at Leica Biosystems. The same analysis told us that we were not playing in the highest growth parts of the market, which for Leica Biosystems is companion diagnostics and pharma services.

There, it was very much around making the internal investments, very clearly bringing the talent who knew how to do these Class III assays, and taking our leadership position in computational pathology to leverage that into what is now a very significant pipeline of pharma deals for quantitative companion diagnostics. It will take a while to see those have a material impact on the P&L. You have to kind of go through the stages of development process, but we think that's exciting and supports higher growth. Then more recently, at LBS, we've done an example of what I believe will be highly strategically compounding M&A with StatLab.

Moderator

I want to hit on M&A in a sec. Before I do that, just back to innovation. Are there particular areas as we think about the next year or two that you would maybe overfund that you could call out that would be priorities?

Julie Sawyer Montgomery
President and CEO, Danaher

Yeah. There's a lot of really strong, important opportunities in our markets. I won't be comprehensive here, but for example, you look at neurodegenerative disease and the opportunity for blood-based biomarker testing in Alzheimer's. That's early days, but there's over 150 drug-modifying therapies in the pipeline. This could become a $5 billion market in 10 years. That's an example of a place that we want to win. Oncology, AI drug discovery, process intensification across advanced modalities in our biotechnology group are all important innovation opportunities for us.

Moderator

Capital deployment, I think you've been clear, M&A is still the priority.

Julie Sawyer Montgomery
President and CEO, Danaher

Yeah.

Moderator

Talk a little bit about some of the lessons learned from the past few years. Anything you want to kind of highlight on the Masimo and StatLab deals? As we go forward, I think you've talked about opportunities across all three platforms. Just talk a little bit about M&A strategy and philosophy.

Julie Sawyer Montgomery
President and CEO, Danaher

Yeah. M&A remains our focus and our priority for capital deployment. We think that's the best place that we can get these long-term compounding returns. We're really looking at that strategically compounding M&A. What that means is companies that have a credible path to differentiated growth that are going to make our platforms stronger and will benefit from being part of our portfolio and from DBS, both on the top and bottom line. You look at our recent acquisitions, we have deployed over $11 billion in capital this year, and Masimo and StatLab represent that. They will have strong high single-digit ROICs by year five or earlier. In terms of capital allocation, we'll continue. You've seen us do some buybacks recently. We'll continue to look at those opportunistically.

We're committed to our dividend, but we're excited about the opportunities to make each of our three platforms stronger through M&A.

Moderator

Other, I guess, as we think about areas you may prioritize, I mean, you're not necessarily big on services. Is that an area you would or would not want to do more in? If we think about bioprocess, you still have some gaps in the portfolio. How do you think about areas where maybe there's some clear white space?

Julie Sawyer Montgomery
President and CEO, Danaher

Yeah. I don't want to comment on particular areas of opportunity today, but I do think that there are opportunities across life sciences, diagnostics, and biotechnology to strengthen our portfolio. We will continue to spend a lot of time looking at those.

Moderator

I think you made a comment on the 3Q earnings call that there were lessons learned from some of the M&A. Can you maybe just touch on that, if we think about Abcam, Aldevron, some of the prior deals?

Julie Sawyer Montgomery
President and CEO, Danaher

Yeah. I think that the M&A playbook at Danaher remains very strong, and we have created a lot of value through M&A. You think about acquisitions like Cytiva, Cepheid, Pall. While I was not involved in some of the companies that you're referencing, I think it's safe to say when you look at Aldevron, for example, that we got the timing of cell and gene therapy kind of taking off a little bit wrong. The lesson that the company has taken away from that is to be very fulsome when looking at the different possibilities for new technology or product adoption curves. M&A remains a strength for us and something that we'll be very active in.

Moderator

You laid out a preliminary framework for next year, 4%-5%. I think most people think that's a good, prudent starting point. Maybe just talk about some of the gives and takes as we think about next year. Obviously, the bioprocessing, the comp will be easier, but talk a little bit about how much, if there is upside, comes from market recovery versus things you can control.

Julie Sawyer Montgomery
President and CEO, Danaher

We've talked about 4%-5% as a starting point for next year, and that 4%-5% core growth ex-respiratory has been where we've been at the last several quarters. I don't want to get into a more developed guide until we have time to go through our normal planning processes here, and then we'll come back in January with a more quantified guide.

Moderator

Got more than halfway through without hitting on AI, so we're going to go there. Talk a little bit about, I guess, just how you're approaching it from a corporate level, how you think about the investments you need to make, how you're interacting with your pharma customers around this.

Julie Sawyer Montgomery
President and CEO, Danaher

Sure. Yeah, I think that AI is a fantastic opportunity for Danaher, both externally and internally. If I start with the external product front, I think that AI drug discovery is going to be an important long-term value creator for Danaher. Personally, I think it's going to make the world a much healthier place. As Danaher, we are well set up to have a leadership position here. Our breadth of portfolio has always mattered, but in the world of AI, it matters more, and that's because we really have all of the building blocks our customers need. We have the instrumentation from companies like SCIEX and Molecular Devices. We have the automation from Beckman Coulter Life Sciences. We have the consumables from Abcam and IDT. We have the software from Genedata and IDBS.

Importantly, we have the scale and breadth that makes us a priority for the frontier labs and for the other players in this innovation ecosystem. We're playing and investing to win here. You may have seen some of our recent announcements. We announced our first autonomous laboratory, the first one, hopefully of many, for affinity reagents. How you can think about this is really, this allows us to connect AI to the physical experiment. Many companies are able to use AI to suggest what that next experiment could be. I remember when I first saw that, I thought it was amazing at the time. But now, we really can, in a closed loop, design the experiment, make the reagent, test the reagent, learn from that, and we're seeing an 8x productivity benefit from that.

Of course, that helps us internally with our R&D productivity, but our pharma, biopharma customers are very interested in this well and how this can help them identify the right reagents. We've also had announcements with NVIDIA around making our instruments smarter, experimenting with digital twins with Anthropic. Then maybe just to comment on the internal opportunity for Danaher. Danaher's Business System really should make us uniquely capable of operationalizing AI, and that is because we truly excel at understanding processes. We know what the critical path of those processes are. We can point our AI at the critical path, and then through our DBS discipline, are really excellent, instead of just having these one-off kind of experiments, turning that into standard work and having the KPIs to ensure that we're sustaining those improvements.

Some of the things that I am excited about, one is schedule compression in R&D. That is a great way to create value and innovation, and we have teams that are improving our schedules by 25%-40%, both by molecular in silico design and also just process improvements in clinical trials and regulatory filings. From a commercial, we are in early days, but we can see how the promise of AI can help us identify opportunities sooner, and also for the big distributed workforce that is a commercial organization, help provide coaching on things like funnel management. We are excited about the progress here.

Moderator

I guess just in terms of leveraging it with innovation and customer products, is that done more through the operating company channels at the corporate level? How do we think about how much is centralized?

Julie Sawyer Montgomery
President and CEO, Danaher

It is done both, right? Every operating company has AI-enabled products and services they are working on. This is part of understanding where that scientific puck is going. We also have things like autonomous laboratory solution that requires coordination across our operating companies. That is a partnership between some talent and capability that we built at corporate, as well as the operating companies. It is going to be very important for us as we turn our breadth into advantage to ensure that we have some operating mechanisms like Danaher laboratory standards, because our customers want to make sure that when they buy from Danaher, these instruments are set up to agentically talk to each other well, that they have common standards for physical AI integration, basically the robotics interfaces, and even one day that they can agentically order from our supply chain.

Setting things up with some commonality is part of how we are rolling out this innovation.

Moderator

As we think about biopharma, I think a lot of the investor focus has shifted upstream to R&D, but obviously, there's a fair amount of AI being applied downstream, correct? On the production side, are you kind of seeing it on both sides? I guess, how do you interpret signal from noise from pharma? Do they really have a good roadmap of where they need to spend on AI, or?

Julie Sawyer Montgomery
President and CEO, Danaher

No, I think this is at the forefront of every customer conversation I have with pharma and biopharma companies. No company wants to be left behind and not gain the benefits. I think that they're investing and experimenting and learning like the rest of us. Our goal is to meet each company where they are at their different levels of maturity and support them with the best AI-enabled workflows possible.

Moderator

Bioprocessing, I just want to spend a minute on. I guess just from your seat, how do you think about the health of the demand drivers there? How do you think about the health of the portfolio? There's an equipment recovery that's maybe starting. How do you think about just what we should be paying attention to next year?

Julie Sawyer Montgomery
President and CEO, Danaher

Sure. Bioprocessing is an area where I've spent significant time since the CEO announcement, and it's clear to me that our Cytiva bioprocessing business is just a fantastic portfolio. We have an unparalleled breadth, which puts us in a position to win with virtually any customer at nearly any stage of the workflow. There's a lot of great attributes of this business. It remains a highly spec'd-in business, which is great to see that level of stickiness, but also some very compelling secular tailwinds. I think about the growth in monoclonal antibodies, the increase in patient access, and therefore volume from the growth of biosimilars, with approximately 100 biologics becoming biosimilars over the next few years. Also, the growth from more advanced modalities outside of the monoclonal antibodies, and the reshoring trend as well.

We feel good about the progress, and this combination of our innovation agenda as well as these secular tailwinds makes us very confident that Cytiva will be a long-term, high single-digit growing business.

Moderator

You have quantified what you think the reshoring opportunity is at about $1 billion and maybe more in 2028 and beyond. I guess maybe just talk about what went into that assumption, and is that based on demand you are seeing today or projections going forward?

Julie Sawyer Montgomery
President and CEO, Danaher

Yep. We have quantified the reshoring opportunity at $1 billion of incremental market growth. Just to give you some color on how we come up with that number, first, we meticulously track all of the reshoring announcements, and then, of course, you have to sort of separate out some of the window dressing from those announcements. We feel like we have good line of sight from that, from extensive conversations with our customers. That $1 billion estimate is what we believe is the true incremental market opportunity that will come to us in the form of our equipment business as part of bioprocessing. We are seeing some early brownfield orders coming through now, but the more larger projects, those greenfield opportunities, are more of the discussion funnel-building phase. That is why we think this becomes more material starting in 2028.

Moderator

I want to spend just a minute on Masimo because this was a deal that you spearheaded and ran. I mean, high single-digit volume grower, leading position in pulse ox. I guess, if we were to look three years from now and look back at the deal as a success, what went right in your view?

Julie Sawyer Montgomery
President and CEO, Danaher

We're really excited by the progress that the team is making at Masimo. High single digits in their first full quarter with Danaher, high single digits year to date. The team is really taking to the Danaher Business System and using it to make a great company greater. They've done over 10 kaizens. We see that success both in terms of lean conversion that's benefiting their margins, as well as building a very attractive funnel of commercial synergy opportunities, both with diagnostics as a whole and with Radiometer in that acute care space. Looking forward, we see this as an example of that great Danaher M&A playbook, where you are increasing margins that allows you to invest more in R&D and commercial, and this is a team that has many more fruitful innovation ideas than they typically have been able to afford.

We're excited about the future.

Moderator

Last question, I guess, what are one or two things you want investors to take away about Danaher's path forward under your leadership?

Julie Sawyer Montgomery
President and CEO, Danaher

Well, ultimately, our success will come through in our financials, and that means higher core growth, unambiguous share gain, and more value creation as that growth transfers through the P&L. Investors should expect to see from us more competitive wins, more signs of us showing up with a connected Danaher value proposition, both commercially and from an innovation standpoint, more impactful organic R&D investments, and us to continue to have really strong capital allocation. We're excited for the future and seeing that come through in higher growth and outperformance in our markets.

Moderator

Great. We'll leave it there. Thanks.

Julie Sawyer Montgomery
President and CEO, Danaher

Thank you.

Moderator

Thank you.